Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nanoparticle-aptamer bioconjugates for cancer targeting.

Omid C Farokhzad1, Jeffrey M Karp, Robert Langer

  • 1Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. ofarokhzad@partners.org

Expert Opinion on Drug Delivery
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Engineering of Intra-Articular Drug Release Profiles Reveals a Key Determinant of Disease-Modifying Efficacy in Post-Traumatic Osteoarthritis.

bioRxiv : the preprint server for biology·2026
Same author

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.

Nature immunology·2026
Same author

Correction: Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays.

Lab on a chip·2026
Same author

A radically simple, ingestible colorimetric biosensor pill for cost-effective, non-invasive monitoring of intestinal inflammation.

Device·2026
Same author

A disease-severity-responsive nanoparticle enables potent ghrelin messenger RNA therapy in osteoarthritis.

Nature nanotechnology·2026
Same author

A Precisely Controlled Long-Acting Immunosuppression Platform Enables Prolonged Survival of Vascularized Composite Allografts.

bioRxiv : the preprint server for biology·2025

This review explores nanoparticle-aptamer bioconjugates for targeted cancer therapy. These advanced drug delivery systems combine controlled release and aptamer targeting for more effective and safer chemotherapy.

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Drug Delivery

Background:

  • Targeted drug delivery and controlled-release systems offer improved cancer therapy.
  • Polymeric nanoparticle-aptamer bioconjugates are an emerging technology for delivering chemotherapeutics to tumors.
  • Aptamers, as short nucleic acid molecules, possess suitable binding and biochemical properties for tumor targeting.

Purpose of the Study:

  • To summarize key components for effective cancer-targeting nanoparticle-aptamer bioconjugates.
  • To discuss controlled release technologies relevant to cancer therapy.
  • To review aptamer structure, properties, and criteria for conjugate construction.

Main Methods:

  • Literature review focusing on nanoparticle-aptamer bioconjugates.

Related Experiment Videos

  • Analysis of controlled-release mechanisms in drug delivery.
  • Examination of aptamer characteristics for molecular targeting.

    • Main Results:

    • Nanoparticle-aptamer bioconjugates integrate targeted delivery with controlled release.
    • Aptamers offer specific binding for enhanced tumor accumulation of therapeutics.
    • Effective conjugate design requires careful consideration of aptamer properties and controlled release strategies.

    Conclusions:

    • Nanoparticle-aptamer bioconjugates represent a promising strategy for advanced cancer chemotherapy.
    • Optimized design of these bioconjugates can lead to enhanced therapeutic efficacy and reduced systemic toxicity.
    • Further research into controlled release and aptamer selection is crucial for clinical translation.